TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual Society of Investigative De...
May 05 2014 - 6:30AM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that data from the phase 1 randomized, placebo-controlled
clinical study of SHAPE (formerly SHP-141) in Stage IA –IIA
Cutaneous T Cell Lymphoma will be presented at the annual Society
of Investigative Dermatology Meeting to be held in Albuquerque, New
Mexico from May 7– May 10, 2014.
The date and time of the poster presentation are as follows:
- Date & Time: Thursday, May 8, 2014 at
12.15pm to 12.25pm Session: Cutaneous T Cell
Lymphoma Symposium International Society for Cutaneous Lymphoma
(ISCL) Scientific and Annual General Meeting Presentation
Title: Tolerability and Encouraging Clinical Activity of
SHP-141, a topical skin restricted HDAC inhibitor, in a phase 1b
study in cutaneous T cell lymphoma Poster # 531
Location: Brazos, Albuquerque Convention
Center
About SHAPE
Suberohydroxamic acid phenyl ester, or SHAPE, is a histone
deacetylase (HDAC) inhibitor being developed for topical use for
the treatment of cutaneous T-cell lymphoma, or CTCL. SHAPE is a
novel therapeutic intentionally designed to maximize HDAC
inhibition locally in the skin with limited systemic exposure. As a
result, SHAPE has characteristics that could allow it to be used
topically over large body surface areas without systemic
absorption. SHAPE demonstrated safety and clinical activity in a
randomized, dose escalation placebo-controlled Phase 1 clinical
trial in early CTCL subjects. A randomized Phase 2 clinical trial
to evaluate SHAPE in early stage CTCL is expected to commence by
the end of 2014. SHAPE's composition of matter patent in the U.S.
extends until at least 2028; in addition, SHAPE has been granted
U.S. orphan drug designation for CTCL. TetraLogic acquired
worldwide development and commercialization rights to SHAPE for all
indications.
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics in
oncology and infectious diseases. TetraLogic has two clinical-stage
product candidates in development: birinapant and suberohydroxamic
acid phenyl ester (SHAPE). Birinapant is currently being tested in
Phase 1 and Phase 2 clinical trials for hematological malignancies
and solid tumors. SHAPE is entering Phase 2 trials for early-stage
CTCL.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future events
or TetraLogic's pre-clinical and clinical development of
birinapant, SHAPE and other clinical programs, future expectations,
plans and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under the heading "Risk
Factors" in our Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 19,2014. Any
forward-looking statements contained in this release speak only as
of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024